Losartan Potassium
Product Images NDC 53002-2624

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 53002-2624). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl530021638)

Losartan Potassium 100 mg tablets packaging label from RPK Pharmaceuticals, Inc. The label shows 30 tablets per container and instructs to take 1 tablet daily or as directed. It includes barcode, NDC information, and spaces for patient and clinic information, as well as warnings about blood pressure treatment and physician consultation.*

FDA Label Image

Label Image (Lbl530021643)

Losartan Potassium 50 mg tablets packaging label from RPK Pharmaceuticals, Inc. The label indicates a package size of 30 tablets with instructions to take 1 tablet daily or as directed. It features prescribing status as Rx only and includes barcode and batch information.*

FDA Label Image

Lbl530022624

Losartan Potassium 25 mg tablets packaging label from RPK Pharmaceuticals, Inc. The label indicates a carton of 30 tablets with instructions to take one tablet daily or as directed. It includes barcode, lot number, expiration date, and space for patient and clinic information.*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

Chemical structure of Losartan Potassium showing the detailed arrangement of atoms and bonds including chlorine, hydroxymethyl, phenyl, and potassium ion components.*

FDA Label Image

Figure 1 (Spl Image2 Figure1)

A line graph comparing the percentage of patients with the primary endpoint over 66 months between Atenolol (dotted line) and Losartan Potassium (solid line). The x-axis represents study months, and the y-axis shows the percentage of patients. The graph notes an adjusted risk reduction of 13% with a p-value of 0.021 for Losartan Potassium versus Atenolol.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 months between Atenolol and Losartan Potassium. The graph shows adjusted risk reduction and statistical significance (p=0.001) favoring Losartan Potassium over the study period.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

A forest plot chart titled 'Primary Endpoint Events within Demographic Subgroups' comparing Losartan Potassium versus Atenolol for primary composite and stroke (fatal/non-fatal) endpoints. The chart presents number of patients, event rates (%), and hazard ratios with 95% confidence intervals across subgroups including age, gender, race, ISH, diabetes, and history of cardiovascular disease. Symbols' sizes represent sample sizes, showing comparative hazard ratios favoring either Losartan Potassium or Atenolol.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium and placebo groups. The graph shows risk reduction of 16.1% with a p-value of 0.022, indicating statistical significance in favor of Losartan Potassium.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.